Zydus Cadila files NDA for Saroglitazar Magnesium
Posted by
www.biotecnika.org
NASH is a progressive disease of the liver and a significant unmet
medical need. There are currently no treatments available for the
treatment of NASH. aroglitazar Mg has previously demonstrated
improvement in both liver enzymes along with favorable effects on
lipid and glycemic indices in patients with nonalcoholic fatty liver
disease in Phase II clinical trials.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-files-nda-for-saroglitazar-magnesium/articleshow/72379297.cms
Subscribe to:
Post Comments (Atom)
Post a Comment